Small-molecule inhibitors targeting viral and host proteins essential for virus replication represent a key strategy for developing antiviral therapies against Enteroviruses and Parechoviruses.
The Enterovirus (EV) and Parechovirus genera of the picornavirus family include many important human pathogens, including poliovirus, rhinovirus, EV-A71, EV-D68, and human parechoviruses (HPeV). They cause a wide variety of diseases, ranging from a simple common cold to life-threatening diseases such as encephalitis and myocarditis. At the moment, no antiviral therapy is available against these viruses and it is not feasible to develop vaccines against all EVs and HPeVs due to the great number of serotypes. Therefore, a lot of effort is being invested in the development of antiviral drugs. Both viral proteins and host proteins essential for virus replication can be used as targets for virus inhibitors. As such, a good understanding of the complex process of virus replication is pivotal in the design of antiviral strategies goes hand in hand with a good understanding of the complex process of virus replication. In this review, we will give an overview of the current state of knowledge of EV and HPeV replication and how this can be inhibited by small-molecule inhibitors.
Linden et al. (Mon,) conducted a review in Enterovirus and Parechovirus infections. Small-molecule inhibitors was evaluated. Small-molecule inhibitors targeting viral and host proteins essential for virus replication represent a key strategy for developing antiviral therapies against Enteroviruses and Parechoviruses.